Effectiveness, safety and treatment adherence of biosimilar follow-on insulin in diabetes management.

Timothy T PhamXiaoxue ChenJohn BarronRichard HartJacob AbarcaAndrea DeVries

Published in: Diabetes, obesity & metabolism (2022)

In patients with type 2 diabetes, Basaglar provided similar glycaemic control compared with Lantus, had a similar safety profile and lower drug costs, and showed more favourable adherence.

Keyphrases

type diabetes
glycemic control
randomized controlled trial
cardiovascular disease
systematic review
emergency department
insulin resistance
weight loss
metabolic syndrome
adipose tissue
adverse drug